CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story

Simply Wall St.03-14 18:21

CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial progress for its gene editing therapy CASGEVY, with higher than expected revenue contribution. The company highlights a threefold increase...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619912669?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-14 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619912669","market":"hk","top_or_hot":-1,"title":"CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story","media":"Simply Wall St.","content":"<div>\n<p>CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial progress for its gene editing therapy CASGEVY, with higher than expected revenue contribution. The company highlights a threefold increase...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-14 18:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial progress for its gene editing therapy CASGEVY, with higher than expected revenue contribution. The company highlights a threefold increase...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val","article_id":"2619912669","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619912669","pubTimestamp":1773483682,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial progress for its gene editing therapy CASGEVY, with higher than expected revenue contribution.\nThe company highlights a threefold increase in projected patient initiations for 2025, signaling growing real world adoption of CASGEVY.\nAlongside CASGEVY traction, CRISPR Therapeutics advances new gene editing programs and partnerships, expanding its clinical pipeline.\n\nCRISPR Therapeutics, trading at $48.75, is moving further into a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4097":"系统软件","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4139":"生物科技","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4588":"碎股","CRSP":"CRISPR Therapeutics AG","PRGS":"Progress Software Corporation","BK4611":"AI医疗"},"translate_title":"CRISPR Therapeutics的CASGEVY进展重塑了增长和估值故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1.5,"PRGS":1.5},"content_text":"CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial progress for its gene editing therapy CASGEVY, with higher than expected revenue contribution. The company highlights a threefold increase in projected patient initiations for 2025, signaling growing real world adoption of CASGEVY. Alongside CASGEVY traction, CRISPR Therapeutics advances new gene editing programs and partnerships, expanding its clinical pipeline.  CRISPR Therapeutics, trading at $48.75, is moving further into a commercial phase as CASGEVY begins to contribute meaningfully to revenue and patient use. The stock has risen 15.7% over the past year, although it remains 62.4% below its level five years ago, highlighting both past volatility and renewed investor interest. For investors, the combination of commercial progress with CASGEVY and a growing pipeline of new gene editing programs indicates that CRISPR Therapeutics is no longer solely a pre-commercial story. The next phase will depend on how CASGEVY adoption develops over time and how effectively the company advances its newer trials and partnerships into additional approved therapies and revenue streams. Stay updated on the most important news stories for CRISPR Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on CRISPR Therapeutics. NasdaqGM:CRSP 1-Year Stock Price Chart Is CRISPR Therapeutics's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At $48.75, CRISPR Therapeutics trades about 42% below the consensus analyst target of $83.74. ✅ Simply Wall St Valuation: The shares are assessed as undervalued, trading 74.5% below the estimated fair value. ✅ Recent Momentum: The 30 day return is roughly 0.9%, suggesting slightly positive short term sentiment as CASGEVY gains traction.  There is only one way to know the right time to buy, sell or hold CRISPR Therapeutics. Head to the Simply Wall St\ncompany report for the latest analysis of CRISPR Therapeutics's Fair Value. Key Considerations  📊 CASGEVY's commercial progress and revenue contribution are now central to the investment case, as CRISPR Therapeutics shifts away from being purely pre commercial. 📊 Watch CASGEVY patient initiations, total revenue, and progress of newer gene editing programs and partnerships into later stage trials. ⚠️ The company remains unprofitable with a net loss of $581.6m and does not yet have meaningful revenue at $3.51m, so funding needs and cash burn are key questions.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete CRISPR Therapeutics analysis. Alternatively, you can visit the\ncommunity page for CRISPR Therapeutics to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619912669","isCrawlerRequest":true}